When was MABXIENCE acquired by FRESENIUS?

MABXIENCE was acquired by FRESENIUS in 2022.

What was the revenue of MABXIENCE at the time of the deal?

The revenue of MABXIENCE at the time of the deal is estimated to be in the range of 250M - 500M EUR.

How is the data for the MABXIENCE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the MABXIENCE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.fresenius.com/10279

← DATABASE

Home Database Healthcare & PharmaMABXIENCE

03/2022

MABXIENCE acquired by FRESENIUS

SPAIN Life Sciences / Pharma & Biotech / CDMO REV 250M - 500M EUR

Context

Fresenius agreed to acquire a 55% majority stake in mAbxience from its founding shareholders, with a contractual put/call option mechanism covering the remaining 45% of the share capital. The acquisition delivers on Fresenius Kabi's core "Broaden Biopharma" growth vector under its Vision 2026 strategy, addressing a critical gap in the division's value chain by adding flexible, single-use biologic drug substance manufacturing capacity. The transaction is expected to generate material operating and cost synergies, primarily driven by leveraging mAbxience's manufacturing capabilities for Fresenius Kabi's existing biosimilars portfolio, and to create an end-to-end integrated biopharmaceutical platform serving both internal programmes and third-party CDMO clients.

By taking control of Mabxience, Fresenius continues its expansion strategy. Previously, the group had completed 2 acquisitions, including Eugin Group in 2020.

MABXIENCE, which reported an EBITDA margin of in 2021, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

mAbxience is a leading international biopharmaceutical company focused on the rapidly developing biosimilars market, founded in 2010 as the biotechnology division of Insud Pharma S.L. The company has established itself as a leader in the development and manufacturing of biological drugs, with two commercialised biosimilar products (Rituximab and Bevacizumab) and a mid-single-digit number of molecules across immunology and oncology expected to be launched globally between 2024 and 2029. mAbxience operates three state-of-the-art biologics manufacturing facilities in Spain and Argentina, supported by internal R&D laboratories, offering highly competitive production costs. In addition to its proprietary biosimilars programmes, mAbxience operates a biologics CDMO business serving third-party clients, including a contract with AstraZeneca to produce the drug substance for its COVID-19 vaccine in Latin America.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2021

2020

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
05/2022	GOLDMAN SACHS	NORGINE	NETHERLANDS	Generics / Labs
05/2022	ASTORG	CORDENPHARMA	SWITZERLAND	CDMO
03/2022	FRESENIUS	IVENIX	UNITED STATES	Diagnostic Equipment
02/2022	MONTAGU PRIVATE EQUITY / PARTNERS GROUP	HTL BIOTECHNOLOGY	FRANCE	CDMO
01/2022	PERMIRA	KEDRION	ITALY	CDMO
01/2022	ANJAC BEAUTY & HEALTH	APOLLO HEALTHCARE CORP.	CANADA	CDMO
01/2022	ARDIAN	BIOFARMA GROUP	ITALY	CDMO
01/2022	PERMIRA	BIO PRODUCTS LABORATORY (BPL)	UNITED KINGDOM	CDMO
12/2021	WINNCARE	PHARMAOUEST INDUSTRIES	FRANCE	Medical Devices
12/2021	THE CARLYLE GROUP / GTCR	RESONETICS	UNITED STATES	Medical Devices

REFERENCES

Revenue range: 250M - 500M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of MABXIENCE by FRESENIUS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: fresenius